BTIG raised the firm’s price target on Exagen (XGN) to $9 from $5 and keeps a Buy rating on the shares. The company delivered a solid Q1 revenue beat driven by strength in average sales price expansion which exceeded the firm’s expectations, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue